OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press50210.17650/1818-8346-2021-16-4-31-39SUPPORTIVE THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИNovel treatment possibilities of invasive aspergillosisНовые возможности терапии инвазивного аспергиллезаhttps://orcid.org/0000-0001-5973-5763KlyasovaG. A.КлясоваГ. А.
Russian Federation

Galina Aleksandrovna Klyasova

4 Novyy Zykovskiy Proezd, Moscow 125167, Russia

Галина Александровна Клясова

Россия, 125167 Москва, Новый Зыковский проезд, 4

klyasova.g@blood.ruNational Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России111120211641011202110112021https://oncohematology.abvpress.ru/ongm/article/view/502

Invasive aspergillosis is the leading fungal infection in patients with hematological malignancies. The review represents the incidence of invasive aspergillosis in different groups of patients, risk factors for its development, treatment options, including the new drug isavuconazole.

Инвазивный аспергиллез является ведущей инфекцией, вызванной грибами, в онкогематологии. в обзоре представлены частота инвазивного аспергиллеза у разных категорий больных, факторы его развития, возможности терапии, включая новый препарат изавуконазол.

invasive aspergillosisinvasive mycosisisavuconazoleинвазивный аспергиллезинвазивный микозизавуконазолСтатья подготовлена при финансовой поддержке компании Пфайзер. В статье выражена позиция автора, которая может отличаться от позиции компании ПфайзерHerbrecht R., Bories P., Moulin J. et al. Risk stratification for invasive aspergillosis. Ann N Y Acad Sci 2012;1272:23–30. DOI: 10.1111/j.1749­6632.2012.06829.x.Pomares H., Arnan M., Sánchez­Ortega I. et al. Invasive fungal infections in AML/ MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 2016;59(8):516–9. DOI: 10.1111/myc.12500.Falantes J.F., Calderón C., MárquezMalaver F.J. et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 2014;14(1):80–6. DOI: 10.1016/j.clml.2013.09.014.Klyasova G.A., Okhmat V.A., Vasilyeva V.A. et al. Invasive mycoses in patients with acute leukemia and in recipients of hematopoietic stem cells. Results of a multicenter prospective observational study in Russia (RIFI). Gematologiya i transfuziologiya = Hematology and Transfusiology 2016;61(1–S1):19. (In Russ.).Клясова Г.А., Охмат В.А., Васильева В.А. и др. Инвазивные микозы у больных острыми лейкозами и у реципиентов гемопоэтических стволовых клеток. Результаты многоцентрового проспективного наблюдательного исследования в России (RIFI). Гематология и трансфузиология 2016;61(1–S1):19.Popova M.O., Zubarovskaya L.S., Klimko N.N. et al. Invasive mycoses in recipients of allogeneic hematopoietic stem cell. Terapevticheskiy arkhiv = Therapeutic Archive 2012;84(7):50–7. (In Russ.).Попова М.О., Зубаровская Л.С., Климко Н.Н. и др. Инвазивные микозы при трасплантации гемопоэтических стволовых клеток. Терапевтический архив 2012;84(7):50–7.Garcia­Vidal C., Upton A., Kirby K.A., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47(8): 1041–50. DOI: 10.1086/591969.Kontoyiannis D.P., Marr K.A., Park B.J. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant­Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010;50(8):1091–100. DOI: 10.1086/651263.Marr K.A., Carter R.A., Boeckh M. et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100(13):4358–66. DOI: 10.1182/blood­2002­05­1496.Robin C., Cordonnier C., Sitbon K. et al. Mainly post­transplant factors are associated with invasive aspergillosis after allogeneic stem cell transplantation: a study from the Surveillance des Aspergilloses Invasives en France and Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant 2019;25(2):354–61. DOI: 10.1016/j.bbmt.2018.09.028.Pagano L., Akova M., Dimopoulos G. et al. Risk assessment and prognosis factors for mould­related diseases in immunocompromised patients. J Antimicrob Chemother 2011;66(S1):i5–14. DOI: 10.1093/jac/dkq437.Tisi M., Hohaus S., Cuccaro A. et al. Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. Haematologica 2017;102(3):e108–e11. DOI: 10.3324/haematol.2016.151837.Morrison V.A. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 2014;59(S5):S360–4. DOI: 10.1093/cid/ciu592.Maschmeyer G., De Greef J., Mellinghoff S. et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) Leukemia 2019;33(4):844–62. DOI: 10.1038/s41375­019­0388­x.Nedel W., Kontoyiannis D., Pasqualotto A. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol 2009;26(3):175–83. DOI: 10.1016/j.riam.2009.04.001.Gil L., Kozlowska­Skrzypczak M., Mol A. et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 2009;43(2):121–6. DOI: 10.1038/bmt.2008.303.Girmenia C. New hematologic populations at risk of invasive aspergillosis: focus on new targeted, biological and cellular therapies. F1000Res 2019;8:F1000 Faculty Rev­1202. DOI: 10.12688/f1000research.17836.1.Dellière S., Dudoignon E., Fodil S. et al. Risk factors associated with Covid­19­associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clinical Microbiology and Infection 2020;27(5):790.e1–5. DOI: 10.1016/j.cmi.2020.12.005.Dimopoulos G., Frantzeskaki F., Poulakou G., Armaganidis A. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci 2012;1272:31–9. DOI: 10.1111/j.1749­6632.2012.06805.x.Klyasova G.A., Petrova N.A., Parovichnikova E.N. et al. Invasive pulmonary aspergillosis. Terapevticheskiy arkhiv = Therapeutic Archive 2003;75(7):63–8. (In Russ.).Клясова Г.А., Петрова Н.А., Паровичникова Е.Н. и др. Инвазивный аспергиллез легких. Терапевтический архив 2003;75(7):63–8.Klyasova G.A., Petrova N.A., Parovichnikova E.N. et al. Invasive pulmonary aspergillosis. Terapevticheskiy arkhiv = Therapeutic Archive 2005;77(7):65–71. (In Russ.).Клясова Г.А., Петрова Н.А., Паровичникова Е.Н. и др. Инвазивный аспергиллез легких. Терапевтический архив 2005;77(7):65–71.Herbrecht R., Denning D.W., Patterson T.F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408–15. DOI: 10.1056/NEJMoa020191.Herbrecht R., Patterson T.F., Slavin M.A. et al. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. Clin Infect Dis 2015;60(5):713–20. DOI: 10.1093/cid/ciu911.Hansford J., Cole C., Blyth C., Gottardo N. Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy. J Antimicrob Chemother 2012;67(7):1807–9. DOI: 10.1093/jac/dks105.Williams K., Mansh M., Chin­Hong P. et al. Voriconazole­associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014;58(7): 997–1002. DOI: 10.1093/cid/cit940.Cornely O.A., Maertens J., Bresnik M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a highloading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44(10):1289–97. DOI: 10.1086/514341.Cornely O.A., Maertens J., Bresnik M. et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011;54(05):e449–55. DOI: 10.1111/j.1439­0507.2010.01947.x.Chandrasekar P.H., Ito J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(S6):S392–400. DOI: 10.1086/429333.Wiley J.M., Seibel N.L., Walsh T.J. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24(2):167–74. DOI: 10.1097/01.inf.0000153183.51258.b8.Ledoux M.P., Guffroy B., Nivoix Y. et al. Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 2020;41(1):80–98. DOI: 10.1055/s­0039­3401990.Maertens J., Raad I., Petrikkos G. et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39(11):1563–71. DOI: 10.1086/423381.Herbrecht R., Maertens J., Baila L. et al. Caspofungin first­line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organisation for Research and Treatment of Cancer Study. Bone Marrow Transplant 2010;45(7):1227–33. DOI: 10.1038/bmt.2009.334.Viscoli C., Herbrecht R., Akan H. et al. Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first­line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009;64(6):1274–81. DOI: 10.1093/jac/dkp355.Marr K.A., Schlamm H.T., Herbrecht R. et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015;162(2):81–9. DOI: 10.7326/M13­2508.Maertens J.A., Raad I.I., Marr K.A. et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised­controlled, non­inferiority trial. Lancet 2016;387(10020):760–9. DOI: 10.1016/S0140­6736(15)01159­9.Marty F.M., Ostrosky­Zeichner L., Cornely O.A. et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single­arm open­label trial and case­control analysis. Lancet Infect Dis 2016;16(7):828–37. DOI: 10.1016/S1473­3099(16)00071­2.Natesan K., Chandrasekar P. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist 2016;9:291–300. DOI: 10.2147/IDR.S102207.Mellinghoff S., Bassetti M., Dörfel D. et al. Isavuconazole shortens the QTc interval. Mycoses 2018;61(4):256–60. DOI: 10.1111/myc.12731.Ullmann A., Aguado J., Arikan­Akdagli S. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID­ECMM­ERS guideline. Clin Microbiol Infect 2018;24(S1):e1–38. DOI: 10.1016/j.cmi.2018.01.002.Tissot F., Agrawal S., Pagano L. et al. ECIL­6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102(3):433–44. DOI: 10.3324/haematol.2016.152900.